Biotechnology

ABEC to expand global manufacturing network with new Wilson facility

ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment and consumables.

Solstice Oncology secures $225m to drive porustobart’s development for cancer

Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.

LSTM opens $23m robotic AI lab for infection research

The Liverpool School of Tropical Medicine (LSTM) in the UK has opened a £20m ($23.2m) robotic AI laboratory to test drugs and vaccines against infections and diseases.

Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule

China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.

Novartis signs deal with Alteogen for drug delivery

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

AusperBio raises $120m to progress hepatitis B therapies

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B (CHB).

Charles River and MVC to develop enterovirus vaccine

Charles River Laboratories International and Medigen Vaccine Biologics (MVC) have entered a collaboration to support the characterisation along with validation of the virus seed bank for the latter’s next-generation multivalent enterovirus vaccine.

FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy

Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).

SandboxAQ introduces AQPotency for virtual drug screening

US-based SandboxAQ has introduced AQPotency, a Large Quantitative Model (LQM) designed to virtually screen and predict the potential of drug candidates without the need for a solved protein structure.